Last reviewed · How we verify
Doxycycline 7 days
Doxycycline 7 days, developed by the University of Oxford, is a marketed antibiotic with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and broad-spectrum antibacterial activity. The primary risk is the potential increase in generic competition following the patent expiry in 2028.
At a glance
| Generic name | Doxycycline 7 days |
|---|---|
| Sponsor | University of Oxford |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Doxycycline to Treat Chlamydial Infection (PHASE4)
- A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity (PHASE1)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Intrauterine Stent Placement Following Hysteroscopic Septum Resection (NA)
- Treatment Responses of Early Syphilis to Ceftriaxone Plus Doxycycline (PHASE4)
- Fecal Molecular Susceptibility-guided Hp First-line Therapy (PHASE4)
- Fecal Molecular Susceptibility-guided Hp Rescue Therapy (PHASE4)
- Scrub Typhus Antibiotic Resistance Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |